ArticleNature communications2022

Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies.

Daniel Re et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.